Skip to main content
idi
Toggle navigation
0
You have 0 notifications
Site Visitor
Site Visitor
New To Inknowvation.com?
Register now to get an access to proprietary SBIR-STTR databases!
Registration is fast and free - start your access to business-actionable information today!
Login
Site Register
SBIR-STTR Award
You are here:
Home
Search Databases
Search SBIR-STTR Awards
SBIR-STTR Award
6
Recombinant Outer Membrane Vesicles as a Novel Adjuvant for a Malaria Vaccine
Award last edited on: 6/17/22
Sponsored Program
SBIR
Awarding Agency
NIH : NIAID
Total Award Amount
$450,000
Award Phase
1
Solicitation Topic Code
NIAID
Principal Investigator
Ly Phan
Company Information
Versatope Therapeutics Inc
110 Canal Street M2D2
Lowell, MA 01852
(857) 526-6657
info@versatope.com
www.versatope.com
Location:
Single
Congr. District:
03
County:
Middlesex
Phase I
Contract Number:
272201800038C-0-0-0
Start Date:
00/00/00
Completed:
00/00/00
Phase I year
2018
Phase I Amount
$450,000
Plasmodium falciparum is the most fatal species of the malaria protozoan parasite infecting humans. The ability to control disease or outbreaks of Pfalciparum malaria with a vaccine has eluded investigators for decades. Innovative adjuvants for malaria vaccines are urgently needed to provide long lasting immune responses and high levels of inhibitory antibodies. We propose to develop a novel malaria vaccine candidate with outer membrane vesicles OMVs derived from a detoxified strain of Escherichia coli which we have shown to be highly effective for multiple strains of influenza in both mice and ferrets. We propose to compare the potency of the OMVs with standard adjuvants by measuring cellular and antibody responses including parasite development and to initiate the work required for scale up process development of the rOMV platform. To induce long lived immune responses we also propose to formulate the rOMVs with poly lactide co glycolide PLGA which we have found works well in influenza models. We propose to measure immune responses one year after immunization. After successfully delivering an effective transmission blocking vaccine candidate for malaria we will propose additional formulation and analytical work to develop a thermo stable vaccine product
Phase II
Contract Number:
----------
Start Date:
00/00/00
Completed:
00/00/00
Phase II year
----
Phase II Amount
----
×
Login to your account
Mail sent successfully.
Enter any username and password.
Username
Password
Remember me
Login
Forgot your username?
Click here for assistance
Forgot your password?
Request new password
Don't have an account?
Sign up
Forgot username?
Mail sent successfully.
Enter username and password.
Please enter email address that is associated with your account.
Back
Submit
Still Need Help?
If you need further assistance, send us an
e-mail
and we will assist you in resetting your account.
Forgot password?
Mail sent successfully.
Enter username and password.
Please enter email address that is associated with your account.
Back
Submit
Still Need Help?
If you need further assistance, send us an
e-mail
and we will assist you in resetting your account.